Have a personal or library account? Click to login
A Review of the Clinical Evidence for Complementary and Alternative Medicine in Huntington’s Disease Cover

A Review of the Clinical Evidence for Complementary and Alternative Medicine in Huntington’s Disease

Tremor and Other Hyperkinetic Movements
Volume 9 (2019): Issue 0
By: Margaret Yu and  Danny Bega  
Open Access
|Aug 2019

References

  1. 1BarbozaL, GhisiN Evaluating the current state of art of Huntington disease research: a scientometric analysis. Braz J Med Biol Res 2018;51(3):e6299. doi: 10.1590/1414-431x2017629929340519
    Back to article
  2. 2BarkerR, MasonSL The hunt for better treatments for Huntington’s disease. Lancet Neurol 2019;18(2):131–133. doi: 10.1016/S1474-4422(18)30448-430563777
    Back to article
  3. 3FrassM, StrasslRP, FriehsH, et al. Use and acceptance of complementary and alternative medicine among the general population and medical personnel: a systematic review. Oschsner J 2012;12(1):45–56.
    Back to article
  4. 4ArmstrongMJ, MiyasakiJM Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology. Neurology 2012;79(6):597–603. doi: 10.1212/WNL.0b013e318263c44322815556
    Back to article
  5. 5WellsRE, PhillipsRS, SchachterSC, et al. Complementary and alternative medicine use among US adults with common neurological conditions. J Neurol 2010;257(11):1822–1831. doi: 10.1007/s00415-010-5616-220535493
    Back to article
  6. 6CooperEL, MaMJ Alzheimer disease: clues from traditional and complementary medicine. J Tradit Complement Med 2017;7(4):380–385. doi: 10.1016/j.jtcme.2016.12.00329034183
    Back to article
  7. 7IpPS, TsimKW, ChanK, et al. Application of complementary and alternative medicine on neurodegenerative disorders: current status and future prospects. Evid Based Complement Alternat Med. 2012;2012:930908. doi: 10.1155/2012/93090823304225
    Back to article
  8. 8FrenchJ, GronsethG Lost in a jungle of evidence: we need a compass. Neurology 2008;71(20):1634–1638. doi: 10.1212/01.wnl.0000336533.19610.1b19001254
    Back to article
  9. 9WahbehH, ElsasSM, OkenBS Mind-body interventions: applications in neurology. Neurology 2008;70(24):2321–2328. doi: 10.1212/01.wnl.0000314667.16386.5e18541886
    Back to article
  10. 10OkeSL, TraceyKJ The inflammatory reflex and the role of complementary and alternative medical therapies. Ann N Y Acad Sci 2009;1172:172–180. doi: 10.1196/annals.1393.01319743552
    Back to article
  11. 11KoelschS A neuroscientific perspective on music therapy. Ann N Y Acad Sci 2009;1169:374–384. doi: 10.1111/j.1749-6632.2009.04592.x19673812
    Back to article
  12. 12FukuiH, AraiA, ToyoshimaK Efficacy of music therapy in treatment for the patients with Alzheimer’s disease. Int J Alzheimers Dis 2012;2012:531646. doi: 10.1155/2012/53164623056992
    Back to article
  13. 13PacchettiC, ManciniF, AglieriR, et al. Active music therapy in Parkinson’s disease: an integrative method for motor and emotional rehabilitation. Psychosom Med 2000;62(3):386–393. doi: 10.1097/00006842-200005000-0001210845352
    Back to article
  14. 14BlumK, SimpaticoT, FeboM, et al. Hypothesizing music intervention enhances brain functional connectivity involving dopaminergic recruitment: common neuro-correlates to abusable drugs. Mol Neurobiol 2017;54(5):3753–3758. doi: 10.1007/s12035-016-9934-y27246565
    Back to article
  15. 15Van Bruggen-RufiMC, VinkAC, WolterbeekR, et al. The effect of music therapy in patients with Huntington’s disease: a randomized controlled trial. J Huntingtons Dis 2017;6(1):63–72. doi: 10.3233/JHD-16022928304313
    Back to article
  16. 16Metzler-BaddeleyC, CanteraJ, CoulthardE, et al. Improved executive function and callosal white matter microstructure after rhythm exercise in Huntington’s disease. J Huntingtons Dis 2014;3(3):273–283.25300331
    Back to article
  17. 17LengT, WoodwardMJ, StokesMJ, et al. Effects of multisensory stimulation in people with Huntington’s disease: a randomized controlled pilot study. Clin Rehabil 2003;17:30–41. doi: 10.1191/0269215503cr582oa12617377
    Back to article
  18. 18KloosA, FritzNE, KostykSK Video game play (dance dance revolution) as a potential exercise therapy in Huntington’s disease: a controlled clinical trial. Clin Rehabil 2013;27(11):972–982. doi: 10.1177/026921551348723523787940
    Back to article
  19. 19TrinklerI, ChehereP, SalguesJ Contemporary dance practice improves motor function and body representation in Huntington’s disease: a pilot study. J Huntingtons Dis 2019;8(1):97–110. doi: 10.3233/JHD-18031530776016
    Back to article
  20. 20EarhartGM Dance as therapy for individuals with Parkinson’s disease. Eur J Phys Rehabil Med 2009;45(2):231–238.19532110
    Back to article
  21. 21JiES, KimYM, ShinMS, et al. Treadmill exercise enhances spatial learning ability through suppressing hippocampal apoptosis in Huntington’s disease rats. J Exerc Rehabil 2015;11(3):133–139. doi: 10.12965/jer.15021226171378
    Back to article
  22. 22SkillingsEA, WoodNI, MortonAJ Beneficial effects of environmental enrichment and food entrainment in the R6/2 mouse model of Huntington’s disease. Brain Behav 2014;4(5):675–686. doi: 10.1002/brb3.23525328844
    Back to article
  23. 23TrembathMK, HortonZA, TippetL A retrospective study of the impact of lifestyle on age at onset of Huntington’s disease. Mov Disord 2010;25(10):1444–1450. doi: 10.1002/mds.2310820629137
    Back to article
  24. 24QuinnL, HamanaK, KelsonM A randomized, controlled trial of a multi-modal exercise intervention in Huntington’s disease. Parkinsonism Relat Disord 2016;31:46–52. doi: 10.1016/j.parkreldis.2016.06.02327423921
    Back to article
  25. 25BusseM, QuinnL, DrewC, et al. Physical activity self-management and coaching compared to social interaction in Huntington disease: results from the ENGAGE-HD randomized, controlled pilot feasibility trial. Phys Ther 2017;97(6):625–639. doi: 10.1093/ptj/pzx03128371942
    Back to article
  26. 26KhalilH, QuinnL, van DeursenR, et al. What effect does a structured home-based exercise programme have on people with Huntington’s disease? A randomized, controlled pilot study. Clin Rehabil 2013;27(7):646–658. doi: 10.1177/026921551247376223426565
    Back to article
  27. 27CruickshankT, ReyesAP, PenaililoLE, et al. Effects of multidisciplinary therapy on physical function in Huntington’s disease. Acta Neurol Scand 2018;138:500–507. doi: 10.1111/ane.1300230058184
    Back to article
  28. 28DawesH, CollettJ, DebonoK, et al. Exercise testing and training in people with Huntington’s disease. Clin Rehab 2015;29(2):192–206. doi: 10.1177/0269215514540921
    Back to article
  29. 29MuellerSM, GehrigSM, PetersenJA, et al. Effects of endurance training on skeletal muscle mitochondrial function in Huntngton disease patients. Orphanet J Rare Diseases 2017;12:184. doi: 10.1186/s13023-017-0740-z29258585
    Back to article
  30. 30FreseS, PetersenJ, Ligon-AuerM Exercise effects in Huntington disease. J Neurol 2017;264:32–39. doi: 10.1007/s00415-016-8310-127747393
    Back to article
  31. 31LamTP Strengths and weaknesses of traditional Chinese medicine and Western medicine in the eyes of some Hong Kong Chinese. J Epidemiol Community Health 2001;55(10):762–765. doi: 10.1007/s00415-016-8310-111553662
    Back to article
  32. 32HaoP, JiangF, ChengJ, et al. Traditional Chinese medicine for cardiovascular disease: evidence and potential mechanisms. J Am Coll Cardiol 2017;69(24):2952–2966. doi: 10.1016/j.jacc.2017.04.04128619197
    Back to article
  33. 33OkamotoH, IyoM, UedaK, et al. Yokukan-san: a review of the evidence for use of this Kampo herbal formula in dementia and psychiatric conditions. Neuropsychiatr Dis Treat 2014;10:1727–1742. doi: 10.2147/NDT.S6525725246794
    Back to article
  34. 34SatohT, TakahashiT, IwasakiK, et al. Traditional Chinese medicine on four patients with Huntington’s disease. Mov Disord 2009;24(3):453–455. doi: 10.1002/mds.2244719133663
    Back to article
  35. 35Perez LloretS, ReyMV, RascolO Ayurveda medicine for the treatment of Parkinson’s disease. J Integrative Med 2013;1(6):1–5. doi: 10.5772/56251
    Back to article
  36. 36XuM, WuZY Huntington disease in Asia. Chin Med J (Engl) 2015;128(13):1815–1819. doi: 10.4103/0366-6999.15935926112725
    Back to article
  37. 37DadhaniaVP, TrivediPP, VikramA, et al. Nutraceuticals against neurodegeneration: a mechanistic insight. Curr Neuropharmacol 2016;14(6):627–640. doi: 10.2174/1570159X1466616010414222326725888
    Back to article
  38. 38KochET, WoodardCL, RaymondLA Direct assessment of presynaptic modulation of cortico-striatal glutamate release in a Huntington’s disease mouse model. J Neurophysiol 2018;120(6):3077–3084. doi: 10.1152/jn.00638.201830332323
    Back to article
  39. 39MiyamotoM, MurphyTH, SchnaarRL, et al. Antioxidants protect against glutamate-induced cytotoxicity in a neuronal cell line. J Pharmacol Exp Ther 1989;250(3):1132–1140.2778712
    Back to article
  40. 40PeyserCE, FolsteinM, ChaseGA, et al. Trial of d-alpha-tocopherol in Huntington’s disease. Am J Psychiatry 1995;152(12):1771–1775. doi: 10.1176/ajp.152.12.17718526244
    Back to article
  41. 41RanenNG, PeyserCE, CoyleJT, et al. A controlled trial of Idebenone in Huntington’s disease. Mov Disord 1996;11(5):549–554. doi: 10.1002/mds.8701105108866496
    Back to article
  42. 42McGarryA, McDermotteM, KieburtzK, et al. A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington’s disease. Neurology 2017;88(2):152–159. doi: 10.1212/WNL.000000000000347827913695
    Back to article
  43. 43The Huntington Study Group A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington’s disease. Neurology 2011;57:397–404. doi: 10.1212/WNL.57.3.397
    Back to article
  44. 44PerryTL, WrightJM, HansenS Failure of aminooxyacetic acid therapy in Huntington disease. Neurology 1980;30(7):772–775. doi: 10.1212/WNL.30.7.7726446691
    Back to article
  45. 45BarrAN, HeinzeW, MendozaJE, et al. Long term treatment of Huntington disease with L-glutamate and pyridoxine. Neurology 1978;28:1280–1282. doi: 10.1212/WNL.28.12.1280153484
    Back to article
  46. 46PazosMR, SagredoO, Fernandez-RuizJ The endocannabinoid system in Huntington’s disease. Curr Pharm Des 2008;14(23):2317–2325. doi: 10.2174/13816120878574010818781982
    Back to article
  47. 47ConsroeP, LagunaJ, AllenderJet al. Controlled Clinical Trial of Cannabidiol in Huntington’s Disease. Pharm BiochemBehav. 1991;40:701-708. doi: 10.1016/0091-3057(91)90386-G
    Back to article
  48. 4848. CurtisA, MitchellI, PatelSet al. A Pilot Study Using Nabilone for Symptomatic Treatment in Huntington’s Disease. Mov Disord. 2009;24(15):2254–2259. doi: 10.1002/mds.2280919845035
    Back to article
  49. 49MorenoJL, CaldenteyJG, CubilloPT, et al. A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington’s disease. J Neurol 2016;263:1390–1400. doi: 10.1007/s00415-016-8145-927159993
    Back to article
  50. 50ElinderF, LiinSI Actions and mechanisms of polyunsaturated fatty acids on voltage-gated ion channels. Front Physiol 2017;8:43. doi: 10.3389/fphys.2017.0004328220076
    Back to article
  51. 51VerbessemP, LemiereJ, EijndeBO, et al. Creatine supplementation in Huntington’s disease: a placebo controlled pilot trial. Neurology 2003;61:925–930. doi: 10.1212/01.WNL.0000090629.40891.4B14557561
    Back to article
  52. 52HerschSM, SchifittoG, OakesD, et al. The CREST-E study of creatine for Huntington disease: a randomized controlled trial. Neurology 2017;89:594–601. doi: 10.1212/WNL.000000000000420928701493
    Back to article
  53. 53BenderA, AuerDP, MerlT, et al. Creatine supplementation lowers brain glutamate levels in Huntington’s disease. J Neurol 2005;252:36–41. doi: 10.1007/s00415-005-0595-415672208
    Back to article
  54. 54TabriziSJ, BlamireAM, MannersDN High-dose creatine therapy for Huntington disease: A 2-year clinical and MRS study. Neurology. 2005;64(9):1655–1656. doi: 10.1212/01.WNL.0000160388.96242.7715883340
    Back to article
  55. 55FerreiraJJ, RosserA, CraufurdD, et al. Ethyl-eicosapentaenoic acid treatment in Huntington’s disease: a placebo-controlled clinical trial. Mov Disord 2015;30(10):1426–1429. doi: 10.1002/mds.2630826175332
    Back to article
  56. 56PuriBK, LeavittBR, HaydenMR, et al. Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial. Neurology 2005;65:286–292. doi: 10.1212/01.wnl.0000169025.09670.6d16043801
    Back to article
  57. 57PuriBK, BydderGM, CounsellSJ, et al. MRI and neuropsychological improvement in Huntington disease following ethyl-EPA treatment. Clin Neurosci 2002;13(1):123–126. doi: 10.1097/00001756-200201210-00029
    Back to article
  58. 58Huntington Study Group Trend-HD Investigators Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease. Arch Neurol 2008;65(12):1582–1589. doi: 10.1001/archneur.65.12.158219064745
    Back to article
  59. 59AdanyeguhIM, RinaldiD, HenryPG, et al. Trihepatanoin improves brain energy metabolism in patients with Huntington disease. Neurology 2015;84:490–495. doi: 10.1212/WNL.000000000000121425568297
    Back to article
  60. 60GoetzCG, TannerCM, CohenJA, et al. L-acetyl-carnitine in Huntington’s disease: double-blind placebo controlled crossover study of drug effects on movement disorder and dementia. Mov Disord 1990;5(3):263–266. doi: 10.1002/mds.870100305
    Back to article
  61. 61CuturicM, AbramsonRK, MoranRR, et al. Serum carnitine levels and levocarnitine supplementation in institutionalized Huntington’s disease patients. Neurol Sci 2013;34:93–98. doi: 10.1007/s10072-012-0952-x22294053
    Back to article
  62. 62HandleyRR, ReidSJ, PatassiniS, et al. Metabolic disruption identified in the Huntington’s disease transgenic sheep model. Sci Rep 2016;6:20681. doi: 10.1038/srep2068126864449
    Back to article
  63. 63van der BurgJMM, GardinerSL, LudolphAC, et al. Body weight is a robust predictor of clinical progression in Huntington disease. Ann Neurol 2017;82(3):479–483. doi: 10.1002/ana.2500728779551
    Back to article
  64. 6464. RuskinDN, RossJL, KawamuraMet al. A ketogenic diet delays weight loss and does not impair working memory or motor function in the R6/2 1J mouse model of Huntington's disease. Physiol Behav 2011;103(5):501–507. doi: 10.1016/j.physbeh.2011.04.00121501628
    Back to article
  65. 65ChenCM, LinYS, WuYR, et al. High protein diet and Huntington’s disease. PLoS One 2015;10(5):e0127654. doi: 10.1371/journal.pone.012765425992839
    Back to article
  66. 66TrejoA, BollMC, AlonsoME, et al. User of oral nutritional supplements in patients with Huntington’s disease. Nutrition 2005;21:889–894. doi: 10.1016/j.nut.2004.12.01216087319
    Back to article
  67. 67AganzoM, MontojoMT, Lopez de Las HazasMC Customized dietary intervention avoid unintentional weight loss and modulates circulating miRNAs footprint in Huntington’s disease. Mol Nutr Food Res 2018;62:1800619. doi: 10.1002/mnfr.201800619
    Back to article
  68. 68MarderK, GuY, EberlyS, et al. Relationship of mediterranean diet and caloric intake to phenoconversion in Huntington disease. JAMA Neurol 2013;70(11):1382–1388. doi: 10.1001/jamaneurol.2013.348724000094
    Back to article
  69. 69MochelF, DuteilS, MarelliC, et al. Dietary anaplerotic therapy improves peripheral tissue energy metabolism in patients with Huntington’s disease. Eur J Hum Genet 2010;18(9):1057–1060. doi: 10.1038/ejhg.2010.7220512158
    Back to article
  70. 70UlanowskiEA, DanzlM, SchwartzV, et al. A qualitative examination of physiotherapist led community-based yoga for individuals with Huntington’s disease. Complement Ther Clin Pract 2017;28:146–151. doi: 10.1016/j.ctcp.2017.06.00228779922
    Back to article
DOI: https://doi.org/10.5334/tohm.509 | Journal eISSN: 2160-8288
Journal RSS Feed
Language: English
Submitted on: May 6, 2019
Accepted on: Aug 1, 2019
Published on: Aug 26, 2019
Published by: Columbia University Libraries/Information Services
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
Huntington’s disease,
CAM,
nutraceuticals,
mind–body

© 2019 Margaret Yu, Danny Bega, published by Columbia University Libraries/Information Services
This work is licensed under the Creative Commons License.

Previous articleVolume 9 (2019): Issue 0Next article